Theriva Biologics shares rise 15.02% intraday after EMA approves VCN-01 Phase 3 trial design.

Theriva Biologics surged 15.02% intraday following European Medicines Agency (EMA) approval for its Phase 3 trial design of VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer. The regulatory milestone validates the therapy’s potential to improve patient outcomes and secures funding for trials through 2027, bolstering investor confidence in the company’s oncology platform. While pre-market trading saw a 5.28% decline amid broader sector rotation, the intraday rebound reflects renewed optimism about the drug’s development trajectory and Theriva’s competitive positioning in the cancer treatment market.